查證：AZ泰國代工廠，旨在供應ASEAN國家

泰國回應蔡總統說法否認阻擋AZ疫苗出口
蔡英文稱泰國優先將AZ疫苗留國內致出貨延遲遭泰否認

【縛雞之見】

According to several new agencies, Thai’s production of AstraZeneca vaccines, which are licensed manufactured by the Siam BioScience, a royal funded corporation, are only to supply the ASEAN countries, meaning there is no room for Siam to supply Taiwan the AZ vaccines.  What the story inside can be? 

20210602　AstraZeneca commences new COVID-19 vaccine supply chain in Thailand

The new supply chain was established in partnership with Siam Bioscience, a leading Thai manufacturer with specialism in biopharmaceutical medicines, to support broad and equitable access to the vaccine in Southeast Asia. AstraZeneca will deliver the first locally produced vaccine doses to Thailand’s Ministry of Public Health, in support of their mass vaccination program. Distribution to other Southeast Asian countries will commence in the coming weeks.

AstraZeneca has established a novel global supply network, with 16 distinct supply chains and 25 manufacturing partners across more than 15 countries. Siam Bioscience is the only manufacturing site of AstraZeneca’s COVID-19 vaccine in Southeast Asia, and it will play a critical role in the supply to other Southeast Asian countries, helping to drive forward Thailand’s Healthcare Strategy of being a regional medical hub.

AstraZeneca has committed to supply its COVID-19 vaccine globally without profit during the pandemic. To date, the company has supplied over 500 million doses to 168 countries.

Siam Bioscience

Siam Bioscience Co., Ltd., the first and only biopharmaceuticals manufacturer in Thailand, was founded in 2009 to preserve and continue in the reign of His Majesty King Rama X what His Majesty King Rama IX had started—to care for the people’s health and wellbeing.

 

 

20210509　AstraZeneca’s COVID-19 vaccines made by Siam Bioscience pass quality testing in Europe and U.S., first batch delivery is near

Our vaccine is well-tolerated, and highly effective against all disease severities and across all adult age groups, according to data from clinical trials in up to 60,000 participants and emerging real-world evidence from tens of millions of people. Our vaccine is well-tolerated, and highly effective against all disease severities and across all adult age groups, according to data from clinical trials in up to 60,000 participants and emerging real-world evidence from tens of millions of people.

20210428　Significant progress on AstraZeneca COVID-19 vaccine production in Thailand

Thailand - regional production hub

“Thailand will play a central role to support our neighbours in Southeast Asia to combat COVID-19, together we can hold hands to fight this pandemic,” said Mr. Teague.

AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorization for emergency use in more than 70 countries, with the World Health Organisation (WHO) Emergency Use Listing now accelerating the pathway to access in up to 142 countries through the COVAX Facility.

 

 

 

タイ、6月の新型コロナワクチン供給量1000万回　接種に遅れも    NewsClip.de 20210609

政府はアストラゼネカとシノバックに加え、米ファイザー、米ジョンソン・エンド・ジョンソン（J&J）などからワクチンを入手し、年内に1億回分を調達する目標を掲げている。タイの総人口はタイ人、外国人合わせ約7000万人。

http://www.newsclip.be/article/2021/06/09/44761.html

 

アストラゼネカの新型コロナワクチン、タイの製造設備が認可取得    Thaiiku 20210429

【タイ】英製薬大手アストラゼネカは28日、同社製の新型コロナウイルスワクチンをタイで製造する予定のサイアムバイオサイエンス社のワクチン製造設備がタイ食品薬品委員会の承認を得たと発表した。6月の供給開始を目指す。
　サイアムバイオサイエンスはアストラゼネカの新型コロナワクチンの東南アジアで唯一の製造拠点となる。年内にタイ国内にワクチン6100万回分を供給するほか、東南アジア諸国連合（ASEAN）諸国に輸出する見通しだ。
　サイアムバイオサイエンスはタイ王室が全額出資する製薬会社。タイの野党の一部は同社とアストラゼネカが契約した経緯や契約の内容が不透明だと批判している。

https://www.thaiiku.com/news_detail/id/209